venerdì, 19 luglio 2024
8 Novembre 2019

Statement on the agency’s efforts to protect patients through postmarket drug safety surveillance practices

November 6, 2019 – Public health and safety is the highest priority at the U.S. Food and Drug Administration. We maintain a robust practice of postmarket surveillance and risk evaluation programs to identify new adverse events that did not appear during the product development process, or to learn more about known adverse events. Evaluations occur on more than two million adverse event reports submitted every year to the FDA Adverse Event Reporting System … (leggi tutto)